BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

38 articles for VJ Lotti

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.EBI
Exploratory Chemistry Merck Sharp and Dohme Research Laboratories
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams.EBI
Merck Sharp & Dohme Research Laboratories
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.EBI
Merck Sharp & Dohme Research Laboratories
Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.EBI
TBA
Novel glutamic acid derived cholecystokinin receptor ligands.EBI
Merck Sharp & Dohme Research Laboratories
alpha-Adrenergic activities of some substituted 2-(aminomethyl)imidazolines.EBI
TBA
 
L-161,638: A potent AT2selective quinazolinone angiotensin II binding inhibitorEBI
TBA
 
AT1 selective angiotensin II antagonists with phenoxyphenylacetic acid as a biphenyl replacement part IEBI
TBA
 
The SAR of 6-(N-alkyl-N-acyl)-2-propyl-3-[(2′-tetrazol-5-yl)biphen-4-yl)methyl]-quinazolinones as balanced affinity antagonists of the human AT1 and AT2 receptorsEBI
TBA
 
α-Phenoxyphenylacetic acid derived angiotensin II antagonists with low nanomolar AT1/AT2 receptor subtype affinity (Part II)EBI
TBA
 
Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT1 and AT2 subtypesEBI
TBA
 
Development of angiotensin II antagonists with equipotent affinity for human AT1 and AT2 receptor subtypes.EBI
TBA
 
A new class of balanced AT1/AT2 angiotensin II antagonists: quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalitiesEBI
TBA
 
Quinazolinone Biphenyl Acylsulfonamides: A potent new class of angiotensin-II receptor antagonistsEBI
TBA
 
Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacementsEBI
TBA
 
Synthesis of new imidazo[1,2-b]pyridazine isosteres of potent imidazo[4,5-b]pyridine angiotensin II antagonistsEBI
TBA
 
Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamideEBI
TBA
 
Quinazolinones 2: QSAR and in vivo characterization of AT1 selective AII antagonistsEBI
TBA
 
Quinazolinones 1: design and synthesis of potent quinazolinone- containing AT1-selective angiotensin-II receptor antagonistsEBI
TBA
 
Benzolactams as non-peptide cholecystokinin receptor ligandsEBI
TBA
 
Multipurpose receptor ligands: β-carboline cholecystokinin antagonistsEBI
TBA
 
Synthesis and structure-activity relationships of a novel series of non-peptide AT2-selective angiotensin II receptor antagonistsEBI
TBA
Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.EBI
Merck Research Laboratories
Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.EBI
Merck Research Laboratories
Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.EBI
Merck Research Laboratories
Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.EBI
Merck Research Laboratories
(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.EBI
Merck Research Laboratories
Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.EBI
Merck Research Laboratories
A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.EBI
Merck Research Laboratories
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.EBI
Merck Research Laboratories
Triazolinone biphenylsulfonamides as angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes.EBI
Merck Research Laboratories
Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.EBI
Merck Research Laboratories
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.EBI
TBA
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.EBI
TBA
Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.EBI
Merck Sharp & Dohme Research Laboratories
N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist.EBI
TBA
Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.EBI
Merck Sharp & Dohme Research Laboratories
Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disordersBDB
Incyte